Danaher: DHR Announces CEO Transition; Reiterates 2026 Guidance

Research evidence excerpt

Danaher: DHR Announces CEO Transition; Reiterates 2026 Guidance

J P M O R G A N North America Equity Research

03 August 2026

Danaher Overweight

DHR, DHR US

DHR Announces CEO Transition; Reiterates 2026 Price (31 Jul 26):$194.98

Guidance

Life Science Tools & Diagnostics

After the close, DHR announced that Julie Sawyer Montgomery has been Casey Woodring AC

appointed President and CEO, effective October 1, 2026. She will succeed current (1-212) 622-9074

CEO Rainer Blair, who will retire and serve as a senior advisor through March 31, casey.woodring@jpmchase.com

2027 to support a seamless transition. When we caught up with management after Marta Nazarovets Zaremba

the announcement, the company was upbeat about Montgomery’s success as head (1-212) 622-6046

of DHR’s Diagnostics business since 2020 and the commercial overhaul she marta.zaremba@jpmchase.com

instituted at Beckman Coulter Diagnostics specifically (Montgomery led Jaden Rismay

commercial operations and R&D at Beckman before becoming President of (1-212) 622-8479

jaden.rismay@jpmchase.com

Diagnostics). That said, it is worth noting that the appointment of Montgomery J.P. Morgan Securities LLC

does not signal a shift in strategy more in favor of Diagnostics, as management

indicated that it feels what Montgomery has done in leveraging the power of the

DHR platform in Diagnostics can be applied effectively to other areas of the

business. In terms of timing, Montgomery will go through a CEO immersion

program before starting in October, which is when DHR begins its forward year

financial planning process (we would expect Montgomery to own 2027 guidance).

Finally, management noted that the equity awards flagged in the announcement are

meant to align the leadership team behind Montgomery moving forward, and the